MDT vs. DXCM, ISRG, ABT, JNJ, NVST, SYK, TMO, BSX, IDXX, and BDX
Should you be buying Medtronic stock or one of its competitors? The main competitors of Medtronic include DexCom (DXCM), Intuitive Surgical (ISRG), Abbott Laboratories (ABT), Johnson & Johnson (JNJ), Envista (NVST), Stryker (SYK), Thermo Fisher Scientific (TMO), Boston Scientific (BSX), IDEXX Laboratories (IDXX), and Becton, Dickinson and Company (BDX). These companies are all part of the "medical" sector.
Medtronic vs. Its Competitors
DexCom (NASDAQ:DXCM) and Medtronic (NYSE:MDT) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings, dividends and media sentiment.
DexCom has a beta of 1.43, indicating that its stock price is 43% more volatile than the S&P 500. Comparatively, Medtronic has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500.
In the previous week, DexCom and DexCom both had 42 articles in the media. Medtronic's average media sentiment score of 1.48 beat DexCom's score of 0.96 indicating that Medtronic is being referred to more favorably in the news media.
Medtronic has higher revenue and earnings than DexCom. Medtronic is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.
Medtronic has a net margin of 13.90% compared to DexCom's net margin of 13.29%. DexCom's return on equity of 30.41% beat Medtronic's return on equity.
DexCom currently has a consensus target price of $99.89, indicating a potential upside of 26.66%. Medtronic has a consensus target price of $98.19, indicating a potential upside of 6.43%. Given DexCom's stronger consensus rating and higher possible upside, analysts plainly believe DexCom is more favorable than Medtronic.
97.8% of DexCom shares are owned by institutional investors. Comparatively, 82.1% of Medtronic shares are owned by institutional investors. 0.3% of DexCom shares are owned by insiders. Comparatively, 0.2% of Medtronic shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
DexCom beats Medtronic on 11 of the 16 factors compared between the two stocks.
Get Medtronic News Delivered to You Automatically
Sign up to receive the latest news and ratings for MDT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MDT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Medtronic Competitors List
Related Companies and Tools
This page (NYSE:MDT) was last updated on 8/8/2025 by MarketBeat.com Staff
